2023年7月12日 · Now, molnupiravir for treatment of RSV is kind of the opposite. This would be not for the pediatric patient population but used to protect the elderly against life-threatening RSV infection. It ...

2023年12月2日 · My doc handed me a script for Molnupiravir, also known as Lagevrio, which I've filled but now I'm sitting on the fence about actually taking it. In the meantime, I'm sticking with the classic combo of ibuprofen, codeine, paracetamol, and pseudoephedrine to manage the symptoms. Keen to hear from anyone who's had experience with Molnupiravir ...

2024年2月21日 · On November 1, 2023, ritonavir-boosted nirmatrelvir and molnupiravir became commercially available. Eligible patients can get COVID-19 antivirals for free or at a reduced cost even if they do not ...

2022年12月22日 · Molnupiravir, even based on the clinical data that got it approved, is nearly a useless drug. Number needed to treat its high even pre vaccine, risk reduction is low, and it's mechanism actually favors mutation of the infecting covid strain. If you're patients are in a pulmonary hypertension clinic they're certainly high risk.

2022年4月20日 · I tested positive on Monday - first time with Covid, I am 53, and high risk with T1 diabetes so was prescribed one of the new antivirals, molnupiravir. I am fully vaxxed and boosted with Moderna but still got it while at Disney. I am just wondering if anyone else here has taken molnupiravir and what your experience was?

2022年3月31日 · 62 votes, 229 comments. Paxlovid is now available for people who qualify as high risk (people age 65+, unvaxed, or with a risk factor).

2022年5月21日 · In those cases it's good to know the relative efficacy of alternatives. It's unfortunate that the other alternatives weren't included such as Early Treatment Remdesivir and Bebtelovimab vs Molnupiravir. Clinicians need this type of comparative data to understand the efficacy trade offs for oral Molnupiravir vs the infused antiviral alternatives.

2021年3月8日 · That led Carlos del Rio, MD, distinguished professor of medicine at Emory University in Atlanta, Georgia, to suggest a future in which a drug like molnupiravir could be taken in the first few days ...

2021年6月18日 · Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups. Conclusions: Molnupiravir is the first oral, direct acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.

2023年8月22日 · Results: Administration of molnupiravir significantly reduced the risk of hospitalization (Odds Ratio [OR] = 0.40, p < 0.001) and death (OR = 0.31, p < 0.001) among these patients based on data adjusted for age, previous SARS-CoV-2 infection, vaccination status, and time elapsed since the most recent vaccination.